Celltelligence’s Post

View organization page for Celltelligence, graphic

582 followers

On Friday, April 5, Johnson & Johnson (press release: https://bit.ly/3PVXMl4) and Legend Biotech (press release: https://bit.ly/3vBlook) announced that the FDA approved #Carvykti (#BCMA CAR-T) for the treatment of adult patients with r/r MM who have received at least one prior LoT, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and are refractory to lenalidomide. On the same day, Bristol Myers Squibb (press release: https://bit.ly/3Ud0pS0) and 2seventy bio (press release: https://bit.ly/3Ucuxgm) announced that #Abecma (BCMA CAR-T) received approval from the FDA for the treatment of adult patients with r/r MM who have received at least 2 prior LoT, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti #CD38 antibody. Celltelligence provides insights on the BCMA CAR-Ts approval in earlier MM lines, while discussing the potential implications: https://bit.ly/CT-865930

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics